Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · iBio, Inc. (IBIO)

iBio updates investor presentation on obesity antibody pipeline

Neutral Impact 2 of 5 other Written later

iBio, Inc. filed an updated corporate presentation dated September 2026 as Exhibit 99.1 to a Form 8-K, for use in meetings with investors and analysts. The filing contains no new financial results, and the presentation reiterates pipeline timelines and a financial snapshot.

Key points

  • Presentation dated September 2026 furnished as Exhibit 99.1 under Items 7.01 and 8.01
  • Pipeline timelines include IBIO-610 IND-equivalent filing expected in 2H 2026 and IBIO-600 interim Phase 1 data anticipated in 1Q 2027
  • Financial snapshot shows $88.0 million in cash, cash equivalents and debt securities as of June 30, 2026, with runway extending into Q4 FY 2028
  • About 64.3 million shares outstanding as of August 30, 2026

The filing

CompanyiBio, Inc. (IBIO)
Form8-K, current report
Filed with the SECSep 14, 2026, 4:16 PM ET
Accession number0001420720-26-000028

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.